Alina Solomon, MD, PhD, University of Eastern Finland, Kuopio, Finland, shares an overview of the findings of an exploratory study looking at the association between genetic risk scores for Alzheimer’s disease (AD) and AD-related neuroimaging measures. A comprehensive genetic risk score has recently been developed based on 83 genome-wide significant variants. At-risk individuals without dementia from the FINGER trial with MRI/PET data were included in the investigation. Preliminary results indicated that overall, genetic risk scores were not related with neuroimaging changes over the two-year follow up, while APOE4 was associated with decreasing hippocampus and total gray matter volumes, and cortical thickness. Over time, less amyloid accumulation was seen in the intervention arm versus the control group in the higher genetic risk score cohort, with no difference seen in the lower genetic risk group. Whereas, when stratified by APOE4 status, less accumulation was seen in the intervention group compared to controls in non-carriers, with no intervention-control difference in carriers. Dr Solomon comments on future work to understand the mechanisms behind these differences. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2023 in Amsterdam, Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
